动脉内重组人血管内皮抑制素联合化疗栓塞术治疗原发性肝癌的疗效及CT灌注参数变化  

Combination of recombinant human endostatin and TACE in treatment of primary hepatic cancer and parameter changes of CT perfusion

作　　者：张泽峰[1] 徐强[1] 黄优华[1] 石红建[1] 沈涛[1] 武洪林[2] 宋蒨[1] 徐元丰[1] 

机构地区：[1]江苏省常州市武进人民医院介入放射科,江苏常州213002 [2]江苏省常州市武进人民医院放射科,江苏常州213002

出　　处：《实用临床医药杂志》2014年第23期73-76,共4页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11321392)

摘　　要：目的探讨动脉内重组人血管内皮抑制素(恩度)联合化疗栓塞术(TACE)治疗原发性肝癌(PHC)前后CT灌注参数变化。方法选取PHC患者40例,随机分为观察组及对照组各20例,对照组给予单纯TACE,观察组给予动脉内恩度联合TACE术,观察术前及术后1个月的CT灌注参数变化。结果 2组间客观缓解率(RR)及不良反应发生率无显著差异(P>0.05),但观察组临床受益率(CBR)显著高于对照组(P<0.05);术后,观察组患者血流量(BF)、肝动脉灌注值(ALP)、肝脏灌注指数(HPI)参数较术前显著下降(P<0.05或P<0.01),且显著优于对照组(P<0.05)。结论动脉内恩度联合TACE术治疗PHC患者能显著提高CBR,不良反应未见显著增加,且CT灌注参数变化显著优于单纯TACE术。Objective To investigate the combination of recombinant human endostatin （endostar） and transhepatic arterial chemotherapy and embolization （TACE） in treatment of primary hepatic cancer （PHC） and related parameter changes of CT perfusion.Methods A total of 40 PHC patients were randomly divided into observation （n =20） and control groups （n =20）.TACE was performed in the control group,and TACE combined endostar was performed in the observation group.Short-term effect and parameter changes of CT perfusion before and 1 month after were observed between 2 groups.Results There was no significant difference in response rate and incidence of adverse reaction between two groups （P 〉 0.05）.Patients in the observation group achieved better clinical benefit rate （CBR） compared to the control group （P 〈 0.05）.After treatment,blood flow （BF）,arterial liver perfusion （ALP） and hepatic perfusion index （HPI） were reduced more in the observation group than those in the control group （P 〈 0.05）.Conclusion Combination of TACE and endostar is an effective and safe way for PHC patients.

关 键 词：原发性肝癌 重组人血管内皮抑制素 经肝动脉化疗栓塞术 CT灌注参数 

分 类 号：R735.7[医药卫生—肿瘤]